Published in Curr Opin Neurol on August 01, 2009
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Human neuroscience and the aging mind: a new look at old problems. J Gerontol B Psychol Sci Soc Sci (2010) 1.67
Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis (2010) 1.28
Beta-amyloid deposition and the aging brain. Neuropsychol Rev (2009) 1.25
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med (2011) 0.94
FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts? Q J Nucl Med Mol Imaging (2011) 0.86
Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis. Eur Radiol (2014) 0.79
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci (2005) 12.85
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci (2009) 12.05
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology (2006) 8.97
Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (2008) 7.95
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron (2005) 7.53
Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol (2004) 7.07
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med (2006) 6.02
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain (2006) 5.42
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (2007) 4.47
Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol (2008) 4.15
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol (2007) 4.11
Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology (2006) 4.06
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain (2007) 2.88
Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry (2002) 2.80
11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology (2007) 2.65
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology (2007) 2.63
Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol (2008) 2.62
Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia (2008) 2.58
Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis (2008) 2.27
Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol (2008) 2.24
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol (2008) 2.19
Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry (2008) 2.12
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 2.04
In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry (2004) 2.04
Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology (2009) 1.70
Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage (2007) 1.53
In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci (2007) 1.52
Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis (2008) 1.39
2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med (2007) 1.37
PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain (2008) 1.34
Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol (2008) 1.31
Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol Aging (2008) 1.31
In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging (2007) 1.29
[11C]PIB binding in Parkinson's disease dementia. Neuroimage (2007) 1.24
Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. Arch Neurol (2007) 1.16
Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med (2009) 1.14
Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol (2009) 1.14
In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem (2008) 1.13
Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology (2007) 0.94
[(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results. Parkinsonism Relat Disord (2007) 0.93
Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene) malononitrile labels prion plaques in vitro. J Neurosci (2003) 0.93